- Home
- MG vs DRUG Comparison
MG vs DRUG Comparison
Compare MG & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MG
- DRUG
- Stock Information
- Founded
- MG 1978
- DRUG 2019
- Country
- MG United States
- DRUG United States
- Employees
- MG N/A
- DRUG N/A
- Industry
- MG Military/Government/Technical
- DRUG Pharmaceuticals and Biotechnology
- Sector
- MG Consumer Discretionary
- DRUG Health Care
- Exchange
- MG Nasdaq
- DRUG Nasdaq
- Market Cap
- MG 309.4M
- DRUG 364.8M
- IPO Year
- MG 2009
- DRUG N/A
- Fundamental
- Price
- MG $11.22
- DRUG $57.60
- Analyst Decision
- MG
- DRUG Strong Buy
- Analyst Count
- MG 0
- DRUG 9
- Target Price
- MG N/A
- DRUG $81.67
- AVG Volume (30 Days)
- MG 158.7K
- DRUG 184.1K
- Earning Date
- MG 11-04-2025
- DRUG 12-30-2025
- Dividend Yield
- MG N/A
- DRUG N/A
- EPS Growth
- MG 60.33
- DRUG N/A
- EPS
- MG 0.57
- DRUG N/A
- Revenue
- MG $715,300,000.00
- DRUG N/A
- Revenue This Year
- MG $1.23
- DRUG N/A
- Revenue Next Year
- MG $2.80
- DRUG N/A
- P/E Ratio
- MG $19.60
- DRUG N/A
- Revenue Growth
- MG N/A
- DRUG N/A
- 52 Week Low
- MG $7.06
- DRUG $23.18
- 52 Week High
- MG $13.43
- DRUG $70.23
- Technical
- Relative Strength Index (RSI)
- MG 51.13
- DRUG 50.03
- Support Level
- MG $12.50
- DRUG $57.01
- Resistance Level
- MG $13.43
- DRUG $61.00
- Average True Range (ATR)
- MG 0.60
- DRUG 3.63
- MACD
- MG -0.06
- DRUG -0.07
- Stochastic Oscillator
- MG 44.72
- DRUG 62.88
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.